Case Report
Published on 14 Nov 2022
RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1019932
- 1,440 views
- Frontiers in Oncology
- Thoracic Oncology
- Articles
Type at least 3 characters
1,600 articles
Articles
Original Research
Published on 14 Nov 2022
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.968064
- 2,525 views
- 4 citations
Original Research
Published on 11 Nov 2022
Stage IV non-small cell lung cancer among young individuals: Incidence, presentations, and survival outcomes of conventional therapies
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.894780
- 2,525 views
- 1 citation
Original Research
Published on 11 Nov 2022
Wedge resection plus adequate lymph nodes resection is comparable to lobectomy for small-sized non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1022904
- 1,904 views
- 3 citations
Editorial
Published on 11 Nov 2022
Editorial: Impact of immunotherapy in lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1083524
- 2,586 views
- 4 citations
Original Research
Published on 10 Nov 2022
Survival analysis and development of a prognostic nomogram for patients with malignant mesothelioma in different anatomic sites
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.950371
- 2,096 views
- 1 citation
Case Report
Published on 10 Nov 2022
Primary pulmonary T-cell lymphoma after operation for small intestinal stromal tumor: A case report
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.926121
- 1,369 views
Systematic Review
Published on 10 Nov 2022
Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.968517
- 2,363 views
- 8 citations
Original Research
Published on 09 Nov 2022
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.909721
- 2,633 views
- 4 citations
Mini Review
Published on 09 Nov 2022
Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.978608
- 1,566 views
- 4 citations
Original Research
Published on 09 Nov 2022
Machine learning identifies characteristics molecules of cancer associated fibroblasts significantly correlated with the prognosis, immunotherapy response and immune microenvironment in lung adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1059253
- 2,085 views
- 5 citations
Original Research
Published on 08 Nov 2022
Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.999606
- 1,610 views
- 3 citations
Original Research
Published on 08 Nov 2022
Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.972972
- 2,273 views
- 5 citations
Case Report
Published on 07 Nov 2022
Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.985446
- 1,573 views
- 3 citations
Case Report
Published on 07 Nov 2022
Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1038774
- 2,926 views
- 5 citations
Systematic Review
Published on 03 Nov 2022
Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.920709
- 3,670 views
- 2 citations